JW Pharmaceutical (001060.KS) Earnings Analysis

JW Pharmaceutical (001060.KS) has no confirmed upcoming earnings date. It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E 8.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 001060.KS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 001060.KS. This page updates as the calendar is published.

001060.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-151,137.7 KRWn/an/an/a
2025-11-031,267.01 KRWn/an/an/a
2025-02-03712 KRW1,375.89 KRW-48.3%Miss
2024-08-01346 KRW527.05 KRW-34.4%Miss

Beat rate: 0/2 (0%) over reported quarters with consensus data.

001060.KS valuation and analyst view

Trailing P/E8.15
Trailing EPS3,125.1 KRW
Price / book1.44
Dividend yield2.70%
Market cap540.39B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is JW Pharmaceutical (001060.KS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 001060.KS. This page updates as the calendar is published.

Did 001060.KS beat earnings last quarter?

Consensus estimate data was not available for 001060.KS's 2026-05-15 report.

What is 001060.KS's earnings track record?

Over the last 2 reported quarters with consensus data, 001060.KS beat estimates 0 times (0%).

What is 001060.KS's current P/E ratio and EPS?

001060.KS trades at a trailing P/E of 8.15 on trailing EPS of 3125.096736138419 KRW.

What do analysts rate 001060.KS?

001060.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.